Zai Lab Ltd

This Glossary includes acronyms and defined terms that are used throughout this report.

ABC: Acinetobacter baumannii-calcoaceticus complex

ABSSSI: Acute bacterial skin and skin structure infections

AChR: Anti-acetylcholine receptor

AD: Atopic dermatitis

ADC: Antibody-drug conjugate

ADS: American Depositary Share, each representing ten of the Company’s ordinary shares

AI: Artificial intelligence

APRIL: A proliferation-inducing ligand

Archives Rules: Provisions on Strengthening Confidentiality and Archives Administration of Overseas Securities Offering and Listing by Domestic Companies

argenx: argenx BV

ASC: Accounting Standard Codification

Asia Pacific: Refers to Greater China, Korea, Vietnam, Thailand, Cambodia, Laos, Malaysia, Indonesia, the Philippines, Singapore, Australia, New Zealand, and Japan, collectively

Audit Committee: The Audit Committee of the Board of Directors

AUGTYRO (Repotrectinib): A next-generation TKI of ROS proto-oncogene 1 (ROS1) tyrosine-protein kinase and of the tropomyosin receptor tyrosine kinases (TRKs) TRKA, TRKB, and TRKC

BAFF: B cell activating factor

BLA: Biologics License Application

BMS: Bristol-Myers Squibb Company

Board of Directors (or Board): The Board of Directors of Zai Lab Limited

BOC HK: Bank of China (Hong Kong) Limited

BOCOM: Bank of Communications Co., Ltd. Shanghai Zhangjiang Sub-Branch

BOC Pudong Branch: Bank of China Pudong Development Zone Sub-Branch

BTD: Breakthrough Therapy Designation

CABP: Community-acquired bacterial pneumonia

CAC: Cyberspace Administration of China

CC: Cervical cancer

cGMPs: Current Good Manufacturing Practices

CI: Confidence interval

-98-

CIB: Industrial Bank Co., Ltd., Shanghai Gubei Branch

CIDP: Chronic inflammatory demyelinating polyneuropathy

CFIUS: U.S. Committee on Foreign Investment

CMB: China Merchants Bank Co., Ltd. Shanghai Branch

CMO: Contract Manufacturing Organization

COBENFY (KarXT): Xanomeline and trospium chloride, a combination of an oral M1/M4-preferring muscarinic acetylcholine receptor agonist and an antimuscarinic agent

Code: The Company’s Code of Business Conduct and Ethics

Commercial Committee: The Commercial Committee of the Board of Directors

Company: Zai Lab Limited and its subsidiaries, collectively

Compensation Committee: The Compensation Committee of the Board of Directors

CRAB: Carbapenem-resistant Acinetobacter strains

CRO: Contract Research Organization

CSRC: China Securities Regulatory Commission

CTA: Clinical trial application

Current Articles: The Sixth Amended and Restated Memorandum and Articles of Association of Zai Lab Limited

D&O: Director and officer

Deciphera: Deciphera Pharmaceuticals, LLC, a subsidiary of Deciphera Pharmaceuticals, Inc.

DLL3: An inhibitor of the Notch ligand that is overexpressed in SCLC and other neuroendocrine neoplasmas

Efgartigimod (efgartigimod alfa fcab or efgartigimod alfa injection): A human IgG1 antibody fragment that binds to FcRn

Efgartigimod SC: The subcutaneous formulation of efgartigimod

EIT: Enterprise income tax

EIT Law: The Enterprise Income Tax Law of the People’s Republic of China

Elegrobart: Immunoglobulin G1-K monoclonal antibody targeting IGF-1R

EMA: European Medicines Agency

Entasis: Entasis Therapeutics Holdings Inc.

ES-SCLC: Extensive-stage small cell lung cancer

EU: European Union

Exchange Act: U.S. Securities Exchange Act of 1934, as amended

FASB: Financial Accounting Standards Board

FCPA: U.S. Foreign Corrupt Practices Act, as amended

-99-

FcRn: The neonatal fragment crystallizable receptor

FDA: U.S. Food and Drug Administration

FGFR2b: Human fibroblast growth factor receptor 2 isoform IIb

Five Prime: Five Prime Therapeutics, Inc.

GBM: Glioblastoma multiforme, an aggressive form of brain tumor

GC: Gastric cancer

GCPs: Good Clinical Practices

GEJ: Gastroesophageal junction

GIST: Gastrointestinal stromal tumors

gMG: Generalized myasthenia gravis

GMPs: Good Manufacturing Practices

Greater China: Mainland China, Hong Kong, Macau, and Taiwan, collectively

GSK: GlaxoSmithKline plc

HABP: Hospital-acquired bacterial pneumonia

Hanhui: Hanhui Pharmaceutical Co., Ltd.

HFCAA: U.S. Holding Foreign Companies Accountable Act, as amended

HGRAC: Human Genetic Resources Administration Office of China

HK Listing Rules: The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended

HKMA: Hong Kong Monetary Authority

HNTE: High and new technology enterprises

Hong Kong (or HK): Hong Kong Special Administrative Region

Hong Kong Stock Exchange (or HKEx): The Stock Exchange of Hong Kong Limited

Huizheng: Huizheng (Shanghai) Pharmaceutical Technology Co., Ltd.

ICI: Immune checkpoint inhibitor

IgAN: IgA nephropathy

IGF-1R: Insulin-like Growth Factor 1 Receptor

IL: Interleukin

IMCCTs: International multi-center clinical trials

IND: Investigational New Drug

Innoviva: Innoviva, Inc.

-100-

IPO: Initial public offering

IV: Intravenous

Karuna: Karuna Therapeutics, Inc.

KarXT: Xanomeline and trospium chloride, a combination of an oral M1/M4-preferring muscarinic acetylcholine receptor agonist and an antimuscarinic agent

KPMG LLP: KPMG LLP, an auditor located in the United States that is inspected by the PCAOB

LRRC15: Leucine-rich repeat-containing protein 15, a type 1 transmembrane protein involved in cell-cell and cell-extracellular matrix interactions that is overexpressed in various mesenchymal tumors where it promotes tumor metastases

MAA: Marketing Authorization Application

Macau: Macau Special Administrative Region

MacroGenics: MacroGenics, Inc.

MediLink: MediLink Therapeutics (Suzhou) Co., Ltd.

MG: Myasthenia gravis

MMAE: Microtubule-disrupting agent monomethyl auristatin E

MOFCOM: China’s Ministry of Commerce

mOS: Median overall survival

mPFS: Median progression-free survival

Nasdaq: Nasdaq Global Market

NDA: New Drug Application

NEC: Neuroendocrine carcinoma

NHSA: China’s National Healthcare Security Administration

Ningbo Bank: Bank of Ningbo Co., Ltd. Suzhou Sub-Branch

Ningbo Bank Agreements: Maximum Credit Contract, Electronic Commercial Draft Discounting Master Agreement and Online Working Capital Loan Master Agreement between Zai Lab Suzhou and Ningbo Bank, collectively

NIST: National Institute of Standards and Technology

NMPA: China’s National Medical Products Administration

Nominating and Corporate Governance Committee: The Nominating and Corporate Governance Committee of the Board of Directors

NovoCure: NovoCure Ltd.

Novo Holdings: Novo Holdings A/S

NRDL: China’s National Reimbursement Drug List

NSCLC: Non-small cell lung cancer

-101-

NTRK: Neurotrophic tropomyosin-receptor kinase

NUZYRA (Omadacycline): A novel tetracycline-class antibacterial with both oral and IV formulations that is a broad-spectrum antibiotic

OPTUNE: Tumor Treating Fields (or TTFields) devices marketed under various brand names, including OPTUNE GIO® for GBM

ORR: Overall response rate

OS: Overall survival

Our commercial products / programs: ZEJULA, VYVGART / VYVGART Hytrulo, NUZYRA, OPTUNE, QINLOCK, XACDURO, and AUGTYRO, collectively

Our securities: Our ADSs and/or ordinary shares, individually or collectively

Ovarian cancer: Epithelial ovarian, fallopian tube, and primary peritoneal cancer, collectively

Paratek: Paratek Bermuda Ltd., a subsidiary of Paratek Pharmaceuticals, Inc.

PANSS: Positive and Negative Syndrome Scale

PARP / PARP Inhibitor: PARP (poly (ADP-ribose) polymerase) is a protein that helps repair DNA damage in cells; PARP inhibitors block PARP from repairing DNA damage, such as may be caused by radiation and/or certain chemotherapies, which may lead to cancer cell death and slow the return or progression of cancer

PBOC: People’s Bank of China

PCAOB: U.S. Public Company Accounting Oversight Board

PDGFRα: Platelet-derived growth factor receptor alpha

PDUFA: U.S. Prescription Drug User Fee Act

PFIC: Passive foreign investment company

Pfizer: Pfizer Inc.

PFS: Pre-filled syringe

PMA: Premarket Approval

pMN: Primary membranous nephropathy

POC: Proof of Concept

Povetacicept: An Fc fusion protein that enhances inhibition of APRIL and BAFF

QINLOCK (Ripretinib): An orally administered switch-control TKI that broadly inhibits KIT and PDGFRα tyrosine kinases, including wild-type and forms with multiple primary mutations or secondary mutations

R&D Committee: The Research and Development Committee of the Board of Directors

RMB: Chinese Renminbi

r/m: Recurrent or metastatic

SAFE: State Administration of Foreign Exchange of China

-102-

SAMR: China’s State Administration for Market Regulation

sBLA: Supplemental Biologics License Application

SC: Subcutaneous

SciClone Pharmaceuticals: SciClone Pharmaceuticals (China) Co., Ltd.

SCLC: Small cell lung cancer

Seagen: Seagen Inc.

SEC: U.S. Securities and Exchange Commission

Securities Act: U.S. Securities Act of 1933, as amended

Security Assessment Measures: The Measures on Security Assessment of Cross-Border Data Transfer

sNDA: Supplemental new drug application

sn-gMG: Seronegative gMG

SOC: Standard of care

SPD Bank: Shanghai Pudong Development Bank Co., Ltd. Zhangjiang Hi-Tech Park Sub-Branch

TCE: T-cell engager

TEAE: Treatment emergent adverse events

TED: Thyroid eye disease

Tesaro: Tesaro, Inc.

TIVDAK (Tisotumab Vedotin): An ADC composed of Genmab’s human monoclonal antibody directed against cell surface tissue factor and Seagen’s ADC technology that utilizes a protease-cleavable linker that covalently attaches MMAE to the antibody

TKI: Tyrosine kinase inhibitor

TMZ: Temozolomide, a chemotherapy drug

TREA: Treatment-related adverse event

Trial Measures: Trial Measures for the Administration of Overseas Issuance and Listing of Securities by Domestic Enterprises

Trust for Life: Our sustainability strategy, which includes three pillars: improve human health, create better outcomes, and act right now with ethical business practices and strong governance

Turning Point: Turning Point Therapeutics, Inc.

U.S.: United States

U.S. GAAP: Generally Accepted Accounting Principles in the United States

VABP: Ventilator-associated bacterial pneumonia

Vertex: Vertex Pharmaceuticals Inc.

-103-

VIEs: Variable interest entities

VYVGART: The brand name for the IV formulation of efgartigimod

VYVGART Hytrulo: The brand name for the SC formulation of efgartigimod

XACDURO (SUL-DUR): A combination of a beta-lactam antibiotic (sulbactam) and beta-lactamase inhibitor (durlobactam)

Zai Lab: Zai Lab Limited, holding company, and its subsidiarieson a consolidated basis

Zai Lab Limited: Zai Lab Limited, a holding company

Zai Lab Shanghai: Zai Lab (Shanghai) Co., Ltd., a wholly-owned subsidiary of the Company

Zai Lab Suzhou: Zai Lab (Suzhou) Co., Ltd., a wholly-owned subsidiary of the Company

Zai Lab US: Zai Lab (US) LLC, a wholly-owned subsidiary of the Company

ZEJULA (Niraparib): An orally administered PARP 1/2 inhibitor

Zenas: Zenas BioPharma (HK) Limited

ZL-1222: A next generation IL-12 potency reduced immunocytokine with two single-chain PD-1 antibody fragments

ZL-1311: a MUC17/CD3 T-cell engager

ZL-1503: A pre-clinical IL-13 / IL-31 bi-specific antibody

ZL-6201: An LRRC15-targeting ADC

Zoci (formerly ZL-1310): Zocilurtatug pelitecan, a next generation DLL3-targeting ADC

1L: First line

2L: Second line

4L: Fourth Line

2015 Plan: Zai Lab Limited 2015 Omnibus Equity Incentive Plan, as amended

2017 Plan: Zai Lab Limited 2017 Equity Incentive Plan

2022 Plan: Zai Lab Limited 2022 Equity Incentive Plan

2025 Annual Report: Annual Report on Form 10-K for the year ended December 31, 2025

2024 Plan: Zai Lab Limited 2024 Equity Incentive Plan

2026 Proxy Statement: Our definitive proxy statement pursuant to Regulation 14A to be filed with the SEC not later than 120 days after the close of our fiscal year ended December 31, 2025

$: U.S. Dollar

-104-

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

-105-

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons in the capacities and on the dates indicated below:

-106-

Index to Consolidated Financial Statements